Espinas Mezcal Ad Client: Espinas Year: 2023 This is placeholder text. To change this content, double-click on the element and click Change Content. To manage all your collections, click on the Content Manager button in the Add panel on the left. Previous Next

At Ablatotech, we are rewriting the rules of medicine by harnessing the body’s natural potential to heal. Born out of the visionary mind of Dr. George Ekema—an award-winning drug discovery scientist and accomplished patent lawyer—Ablatotech stands at the forefront of biotherapeutic innovation. With a profound commitment to transforming lives, we are dedicated to developing groundbreaking technologies that not only trick the body into healing itself but also amplify its innate ability to do so. Pioneering the Future of Healing At Ablatotech, we are rewriting the rules of medicine by harnessing the body’s natural potential to heal and thrive. Born out of the visionary mind of Dr. George Ekema —an award-winning drug discovery scientist and accomplished patent lawyer—Ablatotech stands at the forefront of biotherapeutic innovation. With a profound commitment to transforming lives, we are dedicated to developing groundbreaking technologies that not only trick the body into healing itself but also amplify its innate ability to recover and regenerate. Our flagship innovation, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), is set to redefine the healthcare industry. DAPYTAP enables us to create drugs that are not only safer and more effective than current treatments but also incredibly affordable—reaching even the world’s most underserved populations. Imagine a future where revolutionary therapies are within reach for everyone, from the wealthiest nations to the poorest villages. This is the vision driving Ablatotech forward. Our mission is bold yet clear: to disrupt the healthcare landscape by delivering biotherapeutics that break barriers in accessibility, efficacy, and safety. Through relentless innovation, Ablatotech is poised to lead a paradigm shift, transforming medicine from a system of treatment into one of natural healing and self-repair. For investors seeking to be part of a monumental change in global healthcare, Ablatotech is your opportunity to not only generate impact but to be part of a legacy. Together, we are shaping a world where healing knows no borders, and hope is universal. Welcome to the future of medicine—welcome to Ablatotech.

Learn more about Dr. George M. Ekema, the visionary founder of Ablatotech. An award-winning drug discovery scientist and accomplished patent lawyer, Dr. Ekema is dedicated to advancing biotherapeutics and Dr. George Ekema: Visionary Leader of Ablatotech’s Healthcare Revolution Driven by an unrelenting passion for transforming lives, Dr. George Ekema., cofounder and CEO of Ablatotech, stands as a pioneering force in the world of biotechnology. From a young age, Dr. Ekema exhibited an unquenchable thirst for knowledge, which led him to move to the United States in his teens to pursue a remarkable journey in biomedical sciences. With BS degrees in biology and chemistry, a PhD in biomedical sciences specializing in neuroscience, and a JD in intellectual property law, Dr. Ekema brings a rare blend of scientific mastery and legal expertise to his role as CEO—a combination that uniquely positions him to revolutionize the healthcare industry. With over two decades of experience as a drug discovery and therapeutics scientist, Dr. Ekema's career has been defined by an audacious goal: to cure the incurable. He began by discovering and validating therapeutic targets before advancing into small molecule drug discovery and development. Yet, he quickly recognized that true innovation lies not in inventing external "weapons" to combat disease but in empowering the body’s natural capacity to heal itself. This transformative revelation became the foundation of Ablatotech’s mission. My Story Guided by the principle that the human body, when properly supported, is its own best defender, Dr. Ekema has redefined what is possible in medicine. His leadership at Ablatotech has focused on creating groundbreaking therapeutics—tools that act as "boxing gloves" for the body’s prized fighter, enabling it to deliver knockout blows to cancer, infectious diseases, chronic illnesses, and even aging itself. Ablatotech’s flagship technology, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP) , reflects Dr. Ekema’s visionary approach , delivering safer, highly effective, and incredibly affordable solutions that are accessible to even the most underserved populations. With an inspiring blend of scientific brilliance, entrepreneurial spirit, and humanitarian dedication, Dr. Ekema is not just leading Ablatotech—he is spearheading a global revolution in healthcare. His ability to merge cutting-edge innovation with a deep commitment to equity and impact leaves no doubt that he is the right person to drive the future of medicine forward. At Ablatotech, under Dr. Ekema’s transformative leadership, the vision of delivering the future of medicine today is not just a promise—it’s a rapidly unfolding reality.

Landscape Magazine Photoshoot Client: Landscape Magazine Year: 2023 This is placeholder text. To change this content, double-click on the element and click Change Content. To manage all your collections, click on the Content Manager button in the Add panel on the left. Previous Next

At Ablatotech, we envision a world where healing is no longer a privilege, but a universal right. We are pioneering transformative biotherapeutics that naturally empower the body to heal itself and amplify its innate resilience. Through revolutionary innovations like Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), we are breaking barriers in biotechnology to create safer, more effective, and profoundly affordable treatments that redefine healthcare. Our Vision At Ablatotech, we envision a world where healing is no longer a privilege, but a universal right. Harnessing the extraordinary potential of the human body, we are pioneering transformative biotherapeutics that naturally empower the body to heal itself and amplify its innate resilience. Through revolutionary innovations like Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), we are breaking barriers in biotechnology to create safer, more effective, and profoundly affordable treatments that redefine global healthcare. Imagine a future where life-saving therapies are accessible to every corner of the globe, from bustling cities to the most underserved communities. DAPYTAP not only offers the promise of unparalleled efficacy but also delivers a paradigm shift—drastically reducing costs to make cutting-edge medicine attainable for all. With Ablatotech, we are not just improving lives; we are dismantling outdated systems, disrupting the healthcare industry as we know it, and leading the charge toward a healthier, more equitable world. Invest in Ablatotech, and join us in shaping a future where innovation knows no bounds, and humanity thrives. Together, let’s revolutionize the very foundation of healthcare. Preventing and treating diseases with DAPYTAP No drug can heal the body better than the body can heal itself. Like a prizefighter all the body needs is the right signals and stimulation, like those from DAPYTAP, to completely heal and protect itself. Reversing aging with DAPYTAP We are redefining what is means to grow old. Having a second chance to grow old is within grasp. What would you do with your second chance?

Potential Treatments on the Horizon (other than DAPYTAP) Potential Treatments on the Horizon (Other than DAPYTAP) This is your About page. This space is a great opportunity to give a full background on who you are, what you do and what your site has to offer. Your users are genuinely interested in learning more about you, so don’t be afraid to share personal anecdotes to create a more friendly quality. Every website has a story, and your visitors want to hear yours. This space is a great opportunity to provide any personal details you want to share with your followers. Include interesting anecdotes and facts to keep readers engaged. Double click on the text box to start editing your content and make sure to add all the relevant details you want site visitors to know. If you’re a business, talk about how you started and share your professional journey. Explain your core values, your commitment to customers and how you stand out from the crowd. Add a photo, gallery or video for even more engagement. Let’s Work Together Get in touch so we can start working together.

Join the Groundbreaking Clinical Trials for Tarysol – A Revolutionary Treatment for Thrombosis Are you or a loved one living with blood clot-related health conditions? Ablatotech is conducting clinical trials for Tarysol, a natural, cutting-edge drug designed to rapidly and safely dissolve blood clots within hours. We are seeking volunteers to participate in this pivotal research that has the potential to transform the treatment of thrombosis and improve countless lives. Your participation could help advance medical science and offer new hope for those affected by blood clots. Eligibility Requirements: We are looking for individuals who: Have been diagnosed with thrombosis or related blood clot conditions. Meet specific health criteria as determined during the screening process. Are willing to attend scheduled appointments and adhere to study protocols. Why Participate? Contribute to groundbreaking medical innovation. Access a promising investigational treatment under expert medical supervision. Receive medical care and potential compensation for your time and travel. Your journey as a participant in this study will help shape the future of thrombosis treatment, bringing us closer to safer, more effective solutions for blood clot-related conditions. Contact Us to Learn More If you are interested in participating or would like to know more about the Tarysol clinical trials, please contact: Email: info@ablatotech.com Act now to take part in this life-changing research. Together, we can redefine the future of thrombosis treatment! First Name Last Name Email Location Phone Year of Birth Race Select a Race Ethnicity Enter your ethnicity Gender Select a gender Condition Choose an option I agree to the terms & conditions View terms of use Sign Up Submitted! Thanks for your interest in Tarysol clinical trials.

At Ablatotech, our platform technologies use natural means to stimulate the body to heal itself. Our therapies stimulate natural healing. It is a safer and more efficient way to prevent and cure diseases. For example, with our BACTRAIN technology, we 'train' friendly bacteria, and other beneficial microbes Our Core Technology Direct Antigen Presentation via Yeast for Treating and Preventing Disease (DAPYTAP) At Ablatotech, we are at the forefront of a healthcare revolution, unlocking the body’s inherent capacity to heal itself and amplifying its natural resilience. Our groundbreaking platform, Direct Antigen Presentation via Yeast for the Treatment and Prevention of Disease (DAPYTAP), is redefining what is possible in modern medicine. With DAPYTAP, we are creating a new era of biotherapeutics—safe, highly effective drugs that are remarkably affordable. This innovation enables us to bring life-saving treatments to those in even the most underserved regions, ensuring that cutting-edge healthcare becomes a reality for all, not just a privilege for a few. Ablatotech's vision goes beyond incremental improvements; we aim to disrupt and transform the healthcare industry by making healing accessible, equitable, and revolutionary. By bridging advanced science with practical solutions, we are delivering therapies that set new standards in efficacy and safety, while breaking cost barriers that have long limited global reach. Join us in reshaping the future of medicine—this is innovation with impact, innovation for humanity. Ablatotech is where science meets a profound commitment to improving lives on a global scale. DAPYTAP is a better alternative to monoclonal antibody therapy If it can be treated with monoclonal antibodies, it can be treated better with DAPYTAP. Some of the conditions that DAPYTAP might do much better than monoclonal antibodies include: (1) Kidney transplant rejection (2) Prevention of blood clots in angioplasty (3) Non-Hodgkin lymphoma (4) Prevention of respiratory syncytial virus infection (5) Crohn’s disease (6) Breast cancer (7) Chronic myeloid leukemia (8) Rheumatoid arthritis (9) Asthma (10) Colorectal cancer (11) Multiple sclerosis (12) Macular degeneration (13) Paroxysmal nocturnal hemoglobinuria (14) Psoriasis (15) Muckle-Wells syndrome (16) Rheumatoid and psoriatic arthritis (17) Ankylosing spondylitis (18) Chronic lymphocytic leukemia (19) Bone loss (20) Systemic lupus erythematosus (21) Metastatic melanoma (22) Hodgkin lymphoma (23) Systemic anaplastic large cell lymphoma (24) Castleman disease (25) Gastric cancer (26) Ulcerative colitis (27) Acute lymphoblastic leukemia (28) Non-small cell lung cancer (29) Neuroblastoma (30) Severe eosinophilic asthma (31) High cholesterol (32) Multiple myeloma (33) Soft tissue sarcoma (34) Prevention of Clostridium difficile infection recurrence (35) Bladder cancer (36) Prevention of inhalational anthrax (37) Atopic dermatitis (38) Merkel cell carcinoma (39) Multiple sclerosis (40) Hemophilia A (41) X-linked hypophosphatemia (42) Hereditary angioedema attacks (43) Mycosis fungoides (44) Sézary syndrome (45) Migraine prevention (46) Cutaneous squamous cell carcinoma (47) Primary hemophagocytic lymphohistiocytosis (48) HIV infection (49) Hairy cell leukemia (50) Acquired thrombotic thrombocytopenic purpura (51) Osteoporosis (52) Diffuse large B-cell lymphoma (53) Sickle cell disease

Get in touch with Ablatotech. Reach out to us for inquiries about our groundbreaking innovations, clinical trials, or collaborations. We're here to help and answer your questions. What's on your mind? Get in touch with Ablatotech. Reach out to us for inquiries about our groundbreaking innovations, clinical trials, or collaborations. We're here to help and answer your questions. Please reach out by using this form or email us - info@ablatotech.com info@ablatotech.com First Name Last Name Email Message Send Thanks for submitting!

Terms of Use for Participation in Tarysol Clinical Trials at Ablatotech Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Tarysol clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Your application does not guarantee inclusion in the study; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Tarysol Clinical Trials aim to evaluate the safety, efficacy, and potential applications of Tarysol, a natural compound designed to rapidly solubilize blood clots in veins. By participating, you contribute to medical research aimed at improving healthcare solutions. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation in the trial at any time without consequence. 4. Eligibility Requirements You must meet the eligibility criteria established for the trial, including but not limited to: Age, gender, and health requirements specific to the trial. Absence of certain pre-existing medical conditions as determined by our screening questionnaire or health assessments. 5. Screening and Selection Applicants will undergo a thorough screening process that includes: Completion of detailed questionnaires. Submission of medical records and other requested documentation. Possible physical and diagnostic evaluations. Disclosure of all medications or treatments being used. Ablatotech reserves the right to decline any applicant who does not meet the trial’s criteria or poses a health risk. 6. Privacy and Data Protection Your personal and medical information will be treated as confidential and stored securely. Ablatotech complies with applicable data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Data collected during the trial may be used for research purposes in a de-identified manner. 7. Risks and Benefits Participants must understand the following: Risks: Use of Tarysol may involve side effects, allergic reactions, or unforeseen adverse events. These will be communicated during the informed consent process. Benefits: While personal benefits cannot be guaranteed, participation may contribute to advancements in the treatment of skin disorders. 8. Informed Consent You must sign an Informed Consent Form before participating in the trial. This document provides detailed information about the study, its purpose, procedures, potential risks, and benefits. 9. Participant Responsibilities By participating in the Tarysol clinical trials, you agree to: Follow all instructions provided by the research team. Report any side effects, adverse events, or concerns promptly. Attend all scheduled visits and comply with study protocols. Failure to meet these responsibilities may result in removal from the trial. 10. Compensation Ablatotech may offer compensation for participation, including reimbursement for travel and related expenses. The details of compensation will be outlined before enrollment. 11. Medical Care and Support In the event of injury or adverse effects related to participation in the trial, appropriate medical care will be provided by Ablatotech or its affiliated partners. Details regarding the extent of medical care will be specified in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate your participation in the trial if: You no longer meet the eligibility requirements. You fail to comply with study protocols. Continuation in the trial is deemed unsafe or inappropriate. 13. Intellectual Property Any discoveries, data, or intellectual property resulting from the clinical trial shall remain the sole property of Ablatotech. Participants have no claim to ownership or compensation beyond what is outlined in this document. 14. Limitation of Liability Ablatotech is not liable for any damages beyond those specified in the informed consent, except as required by law. 15. Amendments to Terms Ablatotech reserves the right to modify these Terms of Use at any time. Participants will be notified of any significant changes, and continued participation constitutes acceptance of the revised terms. 16. International Participation Clinical trials for Tarysol are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For questions, concerns, or further information, please contact us at: Email: info@ablatotech.com Acknowledgment and Agreement: By submitting an application for the Tarysol clinical trials, you affirm that you have read and understood these Terms of Use and agree to abide by them.